Alaunos Therapeutics, Inc. (TCRT): Nasdaq/NYSE listing notice — Alaunos Therapeutics transfers to Nasdaq Capital Market; gets 180-day bid price extension to Jan 2, 2024

Alaunos Therapeutics, Inc.

Transfer of Common Stock listing from Nasdaq Global Select to Capital Market approved July 5, effective July 7, 2023.
Company granted additional 180 calendar days until January 2, 2024 to regain $1.00 minimum bid price compliance.
Alaunos intends to consider a reverse stock split if necessary to cure the bid price deficiency.
No assurance the company will regain compliance or meet other Nasdaq listing criteria.
Common stock continues to trade under symbol TCRT on the Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Alaunos Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

July 5, 2023, Nasdaq notified the Company that the Transfer was approved, and that, in connection with the Transfer, the Company was eligible for an additional 180 calendar day period, or until January 2, 2024 (the “Extended Compliance Date”), to regain compliance with the Bid Price Requirement. Effective at the opening of business on July 7, 2023, the Common Stock will be transferred to the Nasdaq Capital Market. The Common Stock will continue to trade under the symbol “TCRT.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, but with less

View on SEC.gov

Browse all listing & compliance notices →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-181966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.